Acetaminophen, Guaifenesin, and Phenylephrine… side effects: what 158,913 FDA adverse event reports show
Drug class
Not stated in label
Who reports
158,913 reports · 59% serious · 12,074 with death outcome · 69% female
Used for
Acetaminophen injection is indicated for • the management of mild to moderate pain in adult and pediatric patients 2 years and older • the management of moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients 2 years and older • the reduction of fever in adult and pediatric patients.
What it is
Paracetamol is a member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.
Boxed warning
RISK OF MEDICATION ERRORS AND HEPATOTOXICITY Take care when prescribing, preparing, and administering acetaminophen injection to avoid dosing errors which could result in accidental overdose and death. In particular,.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,137 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Presbyacusis | 140 | 108.2 86.5–135.5ROR 108.3 · calibrated p 9e-8 ✓ | 58.9 EB05 51.1 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious n=139 · ♀ 100% (drug 69%) · 100% clinician | no trial arm names this drug |
| Blood pressure diastolic abnormal | 1,097 | 98.4 90.9–106.4ROR 99.0 · calibrated p 1e-7 ✓ | 56.2 EB05 53.5 · IC025 +5.7 3/3 methods agree | Lab value / disease marker | serious n=1,021 | no trial arm names this drug |
| Blood pressure systolic abnormal | 973 | 84.6 78.0–91.7ROR 85.1 · calibrated p 4e-7 ✓ | 51.5 EB05 48.8 · IC025 +5.5 3/3 methods agree | Lab value / disease marker | serious n=907 | no trial arm names this drug |
| Subcutaneous drug absorption impaired | 177 | 63.3 52.9–75.8ROR 63.4 · calibrated p 3e-6 ✓ | 42.6 EB05 37.6 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious n=175 · ♀ 100% (drug 69%) · 100% clinician | no trial arm names this drug |
| Neurologic neglect syndrome | 173 | 58.8 49.1–70.3ROR 58.8 · calibrated p 6e-6 ✓ | 40.5 EB05 35.7 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious n=173 · ♀ 100% (drug 69%) · 100% clinician | no trial arm names this drug |
| C-reactive protein | 217 | 41.3 35.4–48.1ROR 41.3 · calibrated p 5e-5 ✓ | 31.4 EB05 28.1 · IC025 +4.7 3/3 methods agree | Lab value / disease marker | serious n=217 · ♀ 100% (drug 69%) · 100% clinician | no trial arm names this drug |
| Deep vein thrombosis postoperative | 448 | 38.9 35.0–43.2ROR 39.0 · calibrated p 6e-5 ✓ | 30.1 EB05 27.8 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious n=448 · ♀ 100% (drug 69%) | no trial arm names this drug |
| Sleep disorder due to general medical condition, insomnia type | 1,439 | 37.8 35.6–40.1ROR 38.1 · calibrated p 7e-5 ✓ | 29.5 EB05 28.2 · IC025 +4.8 3/3 methods agree | Labeled (related wording) related wording | serious n=1,426 · ♀ 97% (drug 69%) · 93% clinician | no trial arm names this drug |
| Lupus vulgaris | 266 | 37.8 33.0–43.3ROR 37.8 · calibrated p 8e-5 ✓ | 29.4 EB05 26.6 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=266 · ♀ 100% (drug 69%) · 100% clinician | no trial arm names this drug |
| X-ray abnormal | 392 | 36.9 33.0–41.3ROR 37.0 · calibrated p 9e-5 ✓ | 28.9 EB05 26.6 · IC025 +4.6 3/3 methods agree | Lab value / disease marker | serious n=392 · ♀ 100% (drug 69%) · 100% clinician | no trial arm names this drug |
| Pleural thickening | 149 | 36.7 30.6–44.0ROR 36.7 · calibrated p 1e-4 ✓ | 28.7 EB05 25.0 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=149 · 100% clinician | no trial arm names this drug |
| Adjustment disorder with depressed mood | 438 | 36.4 32.8–40.5ROR 36.5 · calibrated p 9e-5 ✓ | 28.6 EB05 26.4 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=436 · ♀ 100% (drug 69%) · 100% clinician | no trial arm names this drug |
| Muscle injury | 1,752 | 35.6 33.8–37.6ROR 36.0 · calibrated p 1e-4 ✓ | 28.1 EB05 27.0 · IC025 +4.7 3/3 methods agree | Labeled (related wording) related wording | serious PRR 29.5 · ♀ 100% (drug 69%) · 93% clinician | no trial arm names this drug |
| Carotid artery thrombosis | 176 | 34.1 28.9–40.2ROR 34.1 · calibrated p 1e-4 ✓ | 27.1 EB05 23.9 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=176 · ♀ 100% (drug 69%) · 100% clinician | no trial arm names this drug |
| Autism spectrum disorder | 1,122 | 33.9 31.7–36.2ROR 34.1 · calibrated p 1e-4 ✓ | 27.0 EB05 25.7 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=1,121 · ♀ 37% (drug 69%) · 100% consumer | no trial arm names this drug |
| Anti-cyclic citrullinated peptide antibody | 132 | 32.3 26.7–39.1ROR 32.4 · calibrated p 2e-4 ✓ | 26.0 EB05 22.5 · IC025 +4.3 3/3 methods agree | Lab value / disease marker | serious n=132 · ♀ 100% (drug 69%) · 100% clinician | no trial arm names this drug |
| Anti-cyclic citrullinated peptide antibody positive | 1,323 | 30.0 28.3–31.9ROR 30.3 · calibrated p 3e-4 ✓ | 24.5 EB05 23.4 · IC025 +4.5 3/3 methods agree | Lab value / disease marker | serious PRR 23.9 · ♀ 100% (drug 69%) · 95% clinician | no trial arm names this drug |
| Temperature regulation disorder | 405 | 29.8 26.8–33.2ROR 29.9 · calibrated p 3e-4 ✓ | 24.4 EB05 22.5 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=401 · ♀ 100% (drug 69%) | no trial arm names this drug |
| Pleural fibrosis | 184 | 28.5 24.3–33.5ROR 28.5 · calibrated p 4e-4 ✓ | 23.5 EB05 20.8 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=184 · ♀ 100% (drug 69%) | no trial arm names this drug |
| Duodenal ulcer perforation | 1,297 | 28.1 26.5–29.9ROR 28.4 · calibrated p 4e-4 ✓ | 23.3 EB05 22.2 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious PRR 22.6 · ♀ 100% (drug 69%) · 94% clinician | no trial arm names this drug |
| Dislocation of vertebra | 393 | 28.1 25.2–31.4ROR 28.2 · calibrated p 4e-4 ✓ | 23.3 EB05 21.4 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=393 · ♀ 100% (drug 69%) · 100% clinician | no trial arm names this drug |
| Folliculitis | 1,812 | 27.9 26.5–29.4ROR 28.2 · calibrated p 4e-4 ✓ | 23.1 EB05 22.2 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious PRR 26.2 · ♀ 100% (drug 69%) · 93% clinician | no trial arm names this drug |
| Swollen joint count increased | 531 | 26.9 24.5–29.5ROR 27.0 · calibrated p 5e-4 ✓ | 22.4 EB05 20.9 · IC025 +4.3 3/3 methods agree | Lab value / disease marker | serious n=530 · ♀ 100% (drug 69%) · 100% clinician | no trial arm names this drug |
| Blood magnesium increased | 132 | 22.4 18.6–27.0ROR 22.4 · calibrated p 0.001 ✓ | 19.2 EB05 16.6 · IC025 +3.9 3/3 methods agree | Lab value / disease marker | serious n=129 · ♀ 100% (drug 69%) · 100% clinician | no trial arm names this drug |
| Rheumatic fever | 617 | 21.6 19.8–23.5ROR 21.6 · calibrated p 0.001 ✓ | 18.6 EB05 17.4 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=617 · ♀ 100% (drug 69%) · 100% clinician | no trial arm names this drug |
| Adjustment disorder | 181 | 21.1 18.0–24.7ROR 21.1 · calibrated p 0.002 ✓ | 18.3 EB05 16.1 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=180 · ♀ 100% (drug 69%) · 100% clinician | no trial arm names this drug |
| Helicobacter infection | 1,404 | 20.9 19.8–22.1ROR 21.1 · calibrated p 0.002 ✓ | 18.2 EB05 17.4 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious PRR 18.6 · ♀ 100% (drug 69%) · 92% clinician | no trial arm names this drug |
| Rheumatoid factor positive | 782 | 20.5 19.1–22.2ROR 20.6 · calibrated p 0.002 ✓ | 17.9 EB05 16.8 · IC025 +4.0 3/3 methods agree | Lab value / disease marker | serious n=782 · ♀ 100% (drug 69%) · 100% clinician | no trial arm names this drug |
| Retinitis | 209 | 18.8 16.2–21.7ROR 18.8 · calibrated p 0.003 ✓ | 16.5 EB05 14.7 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=209 · ♀ 100% (drug 69%) · 100% clinician | no trial arm names this drug |
| Hand deformity | 1,559 | 17.7 16.8–18.7ROR 17.9 · calibrated p 0.003 ✓ | 15.7 EB05 15.1 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious PRR 16.5 · ♀ 100% (drug 69%) | no trial arm names this drug |
| Chronic kidney disease-mineral and bone disorder | 127 | 17.5 14.6–21.1ROR 17.5 · calibrated p 0.004 ✓ | 15.5 EB05 13.4 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=127 · ♀ 0% (drug 69%) | no trial arm names this drug |
| C-reactive protein abnormal | 745 | 17.2 16.0–18.6ROR 17.3 · calibrated p 0.004 ✓ | 15.3 EB05 14.4 · IC025 +3.8 3/3 methods agree | Lab value / disease marker | serious n=743 · ♀ 100% (drug 69%) · 90% clinician | no trial arm names this drug |
| Pemphigus | 1,431 | 17.0 16.1–18.0ROR 17.2 · calibrated p 0.004 ✓ | 15.2 EB05 14.5 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious PRR 14.8 · ♀ 97% (drug 69%) · 94% clinician | no trial arm names this drug |
| Facet joint syndrome | 360 | 16.9 15.1–18.8ROR 16.9 · calibrated p 0.004 ✓ | 15.0 EB05 13.8 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=357 · ♀ 100% (drug 69%) | no trial arm names this drug |
| Nephrogenic anaemia | 515 | 16.2 14.8–17.8ROR 16.3 · calibrated p 0.005 ✓ | 14.5 EB05 13.5 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=515 | no trial arm names this drug |
| Hyperparathyroidism secondary | 278 | 16.2 14.3–18.3ROR 16.2 · calibrated p 0.005 ✓ | 14.4 EB05 13.1 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=277 | no trial arm names this drug |
| Peripheral venous disease | 420 | 15.4 13.9–17.0ROR 15.4 · calibrated p 0.006 ✓ | 13.8 EB05 12.8 · IC025 +3.6 3/3 methods agree | Labeled (related wording) related wording | serious n=415 · ♀ 100% (drug 69%) · 100% clinician | no trial arm names this drug |
| Synovitis | 1,818 | 14.7 14.0–15.4ROR 14.8 · calibrated p 0.007 ✓ | 13.3 EB05 12.8 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious PRR 13.5 · ♀ 95% (drug 69%) | no trial arm names this drug |
| Bronchial secretion retention | 127 | 14.6 12.2–17.6ROR 14.6 · calibrated p 0.008 ✓ | 13.2 EB05 11.3 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=126 · ♀ 100% (drug 69%) · 100% clinician | no trial arm names this drug |
| Blood pressure diastolic decreased | 744 | 14.6 13.5–15.8ROR 14.7 · calibrated p 0.008 ✓ | 13.2 EB05 12.4 · IC025 +3.6 3/3 methods agree | Lab value / disease marker | serious PRR 12.9 | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Serious infection | 13,866 | 2.42.4–2.4 | signal |
| Liver injury | 5,401 | 2.42.3–2.4 | signal |
| Fall / fracture | 6,340 | 2.22.2–2.3 | signal |
| Tendon disorder | 581 | 2.01.9–2.2 | raised |
| Interstitial lung disease | 1,413 | 2.01.9–2.1 | raised |
| Depression | 3,944 | 1.91.8–1.9 | raised |
| Anaemia | 4,131 | 1.81.8–1.9 | raised |
| Kidney injury | 6,157 | 1.81.7–1.8 | raised |
| Gi bleeding | 2,431 | 1.81.7–1.8 | raised |
| Opportunistic infection | 1,725 | 1.71.6–1.8 | raised |
| Thrombocytopenia | 2,700 | 1.61.6–1.7 | raised |
| Venous thromboembolism | 2,577 | 1.61.5–1.6 | raised |
| Arrhythmia / qt | 2,106 | 1.41.4–1.5 | raised |
| Hyponatraemia | 818 | 1.31.3–1.4 | raised |
| Hyperglycaemia / diabetes | 3,313 | 1.31.2–1.3 | raised |
| Pancreatitis | 724 | 1.21.1–1.3 | raised |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug ineffective (drug did not work) | 17,295 | 1.7 1.7–1.8ROR 1.8 · calibrated p 0.849 | 1.7 EB05 1.7 · IC025 +0.8 | Reporting / coding artifact | age-adj. PRR 1.8 · serious PRR 2.4 | no trial arm names this drug |
| Fatigue (tiredness) | 16,682 | 2.9 2.8–2.9ROR 3.1 · calibrated p 0.597 | 2.8 EB05 2.8 · IC025 +1.5 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.9 · serious PRR 3.7 | no trial arm names this drug |
| Headache | 13,549 | 2.9 2.8–2.9ROR 3.1 · calibrated p 0.604 | 2.9 EB05 2.8 · IC025 +1.5 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 3.0 · serious PRR 3.8 | no trial arm names this drug |
| Pain | 13,296 | 2.9 2.8–2.9ROR 3.1 · calibrated p 0.606 | 2.8 EB05 2.8 · IC025 +1.5 3/3 methods agree | Likely indication confounding term in indications; also in warnings | age-adj. PRR 3.5 · serious PRR 3.4 | no trial arm names this drug |
| Nausea | 13,199 | 2.2 2.2–2.3ROR 2.3 · calibrated p 0.885 | 2.2 EB05 2.2 · IC025 +1.1 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.3 · serious PRR 2.9 | no trial arm names this drug |
| Off label use (used outside approved label) | 12,429 | 1.9 1.9–1.9ROR 2.0 · calibrated p 0.932 | 1.9 EB05 1.9 · IC025 +0.9 | Reporting / coding artifact | age-adj. PRR 1.7 · serious PRR 2.6 | no trial arm names this drug |
| Diarrhoea (diarrhea) | 11,266 | 2.3 2.3–2.4ROR 2.4 · calibrated p 0.841 | 2.3 EB05 2.3 · IC025 +1.2 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.3 · serious PRR 2.7 | no trial arm names this drug |
| Arthralgia (joint pain) | 10,390 | 3.4 3.3–3.4ROR 3.5 · calibrated p 0.477 | 3.3 EB05 3.3 · IC025 +1.7 3/3 methods agree | Not in label — unassessed | age-adj. PRR 3.4 · serious PRR 4.6 | no trial arm names this drug |
| Dyspnoea (shortness of breath) | 10,178 | 2.4 2.4–2.4ROR 2.5 · calibrated p 0.816 | 2.4 EB05 2.3 · IC025 +1.2 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.4 · serious PRR 2.7 | no trial arm names this drug |
| Vomiting | 7,657 | 2.2 2.1–2.2ROR 2.2 · calibrated p 0.936 | 2.2 EB05 2.1 · IC025 +1.1 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.2 · serious PRR 2.4 | no trial arm names this drug |
| Pyrexia (fever) | 7,599 | 2.9 2.9–3.0ROR 3.0 · calibrated p 0.615 | 2.9 EB05 2.8 · IC025 +1.5 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.8 · serious PRR 3.0 | no trial arm names this drug |
| Rash | 7,575 | 2.3 2.3–2.4ROR 2.4 · calibrated p 0.860 | 2.3 EB05 2.3 · IC025 +1.2 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 2.5 · serious PRR 3.7 | no trial arm names this drug |
| Dizziness | 7,523 | 2.0 2.0–2.1ROR 2.1 · calibrated p 0.975 | 2.0 EB05 2.0 · IC025 +1.0 | Not in label — unassessed | age-adj. PRR 2.1 · serious PRR 2.4 | no trial arm names this drug |
| Asthenia (weakness) | 7,466 | 2.7 2.6–2.7ROR 2.7 · calibrated p 0.720 | 2.6 EB05 2.6 · IC025 +1.3 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.6 · serious PRR 2.9 | no trial arm names this drug |
| Pruritus (itching) | 6,756 | 2.4 2.3–2.4ROR 2.4 · calibrated p 0.838 | 2.4 EB05 2.3 · IC025 +1.2 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.4 · serious PRR 3.9 | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Presbyacusis — n=140, PRR 108.2
- Subcutaneous drug absorption impaired — n=177, PRR 63.3
- Neurologic neglect syndrome — n=173, PRR 58.8
- Deep vein thrombosis postoperative — n=448, PRR 38.9
- Lupus vulgaris — n=266, PRR 37.8
- Pleural thickening — n=149, PRR 36.7
- Adjustment disorder with depressed mood — n=438, PRR 36.4
- Carotid artery thrombosis — n=176, PRR 34.1
- Autism spectrum disorder — n=1,122, PRR 33.9
- Temperature regulation disorder — n=405, PRR 29.8
✓ A hand-written Bradford Hill causality assessment exists for this drug: Acetaminophen (paracetamol) ↔ Liver injury / hepatotoxicity.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Acetaminophen, Guaifenesin, and Phenylephrine…?
In FDA FAERS, the most frequently co-reported reaction terms for Acetaminophen, Guaifenesin, and Phenylephrine… are fatigue, headache, pain, nausea, diarrhoea, arthralgia. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Acetaminophen, Guaifenesin, and Phenylephrine… have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: RISK OF MEDICATION ERRORS AND HEPATOTOXICITY Take care when prescribing, preparing, and administering acetaminophen injection to avoid dosing errors which could result in accidental overdose and death. In particular,.
Do FAERS signals prove that Acetaminophen, Guaifenesin, and Phenylephrine… causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 0f67c1bd-915b-4681-88dd-22f5154a80b3, effective 20240506; matched on
openfda.generic_name.exact:"ACETAMINOPHEN" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - PubChem CID 1983 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,177 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
ACETAMINOPHEN, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.